Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Emibetuzumab [USAN:INN]
RN: 1365287-97-3
UNII: MO4K3GDN1I

Note

  • Targets the HGF receptor

    NCI: A humanized IgG4 monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-MET) with potential antineoplastic activity. Anti-c-MET monoclonal antibody LY2875358 binds to c-MET, thereby preventing the binding of HGF to its receptor c-Met and subsequent activation of the HGF/c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis. (NCI Thesaurus)

Molecular Formula

  • C6356-H9810-N1694-O2014-S48
 

Classification Code

  • Antineoplastic
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Emibetuzumab [USAN:INN]

Synonyms

  • Emibetuzumab
  • LY-2875358
  • LY2875358
  • UNII-MO4K3GDN1I

Systematic Name

  • Immunoglobulin G4, anti-(human hepatocyte growth factor receptor) (human-Mus musculus monoclonal LY2875358 gamma4-chain), disulfide with human-Mus musculus monoclonal LY2875358 kappa-chain, dimer

Registry Numbers

CAS Registry Number

  • 1365287-97-3

FDA UNII

  • MO4K3GDN1I

System Generated Number

  • 1365287973